Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "University-of-Sydney"

3 News Found

Universal COVID-19 vaccine can be game-changer for developing countries like India, says GlobalData
News | October 11, 2022

Universal COVID-19 vaccine can be game-changer for developing countries like India, says GlobalData

The Coalition for Epidemic Preparedness Innovations (CEPI) has recently partnered with the consortium of India-based Bharat Biotech, University of Sydney and ExcellGene to develop “variantproof” COVID-19 vaccine.

Merck’s pembrolizumab demonstrates improvement in distant metastasis
News | June 06, 2022

Merck’s pembrolizumab demonstrates improvement in distant metastasis

Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).

CEPI partners with Bharat Biotech, Unversity of Sydney and ExcellGene to develop variant proof Covid-19 vaccine
Biotech | May 10, 2022

CEPI partners with Bharat Biotech, Unversity of Sydney and ExcellGene to develop variant proof Covid-19 vaccine

CEPI will provide funding of up to US $19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium

Latest Stories

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

ASG opens its branch of super-specialty eye hospitals in Noida

Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

White Papers

Chasing Consistency: Centralizing operations data is the key to optimizing chemicals plants

Implementing a digital transformation in chemical operations to maximize profitability

The complexity of compliance

The Sprint to the Summit: Unlocking Lab Efficiency through Digital Transformation

The guiding role of fluidized and spouted bed technologies in particle building processes

Interviews
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Capex commitment likely to be in the range of Rs. 200-300 Cr: Dr. R. Ananthanarayanan, CEO, Sajjan India
Dr. R. Ananthanarayanan CEO, Sajjan India
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Our focus is on organic expansion and building our own plants...: Dr. Aman Desai, Promoter and Whole Time Director, Aether Industries
Dr. Aman Desai Promoter and Whole Time Director, Aether Industries
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
We have consistently expanded our business in India: Vinod Paremal, President & MD, Evonik, India Region
Vinod Paremal President & MD, Evonik, India Region

Packaging